Mangoceuticals' TRT Program Sees 336% Sales Surge in Just Months

Mangoceuticals, Inc. (NASDAQ: MGRX) has announced strong early success for its newly launched injectable Testosterone Replacement Therapy (TRT) program. Priced at $99 per month, the all-inclusive service covers doctor visits, lab work, and medication—all prescribed through licensed healthcare providers. Sales have surged since its mid-December debut, reflecting rising demand for accessible TRT solutions.

The company's injectable TRT program has seen a 336% month-over-month increase in sales since launch. At the same time, customer acquisition costs have dropped by 54%, a sign of both growing interest and more efficient marketing. Jacob Cohen, Founder and CEO of Mangoceuticals, highlighted the rapid uptake and accelerating sales as key indicators of the program's early impact.

Beyond TRT, MangoRx is expanding its telehealth platform to offer a broader range of men's health and wellness services. While the company plans to diversify, it remains focused on patient safety and regulatory compliance, ensuring all treatments are overseen by licensed professionals. The global TRT market, valued at around $2.11 billion to $2.2 billion in 2025, is projected to grow at a steady rate of 3.9% annually.

Mangoceuticals expects TRT to remain its primary growth driver. Future investments will target advancements in both injectable and oral TRT formulations, aiming to meet evolving patient needs.

The injectable TRT program's rapid growth and cost efficiencies point to a promising start for Mangoceuticals. With plans to expand its telehealth services and refine its TRT offerings, the company is positioning itself to capitalise on a multi-billion-dollar market. All treatments will continue to be delivered through licensed providers, maintaining strict adherence to safety and compliance standards.